DBV Technologies S.A. issued a press release regarding its BLA submission update for the VIASKIN® Peanut Patch for children aged 4 through 7 years. The company is working collaboratively with the FDA to optimize the review process in preparation for filing. DBV Technologies S.A. is a biotechnology company focused on developing medical treatments for peanut allergies.

DBV Technologies S.A. approved its 2026 Performance Share Unit Plan and granted 4,060,000 performance share units (PSUs) to CEO Daniel Tassé. The award is contingent upon FDA approval of Viaskin Peanut biologics license applications, with 2,900,000 PSUs vesting upon the first approval and 1,160,000 PSUs vesting upon a second approval.